Revolutionary AlphaDBS Wins CE Mark, Paving the Way for Smarter Parkinson’s Treatment

A major breakthrough in Parkinson’s treatment is on the horizon as Newronika’s AlphaDBS secures CE Mark approval, making it the first adaptive deep brain stimulation (DBS) system ready for European markets. Unlike traditional DBS, which delivers constant stimulation, AlphaDBS uses real-time brain signals to automatically adjust stimulation levels. This personalized approach enhances symptom control, reduces side effects, and minimizes neurologist visits, offering a smoother, more natural experience for patients.

With this regulatory win, Newronika is gearing up for a 2025 European launch, bringing cutting-edge neuromodulation technology to people living with Parkinson’s disease and other neurological disorders. Clinical studies show that AlphaDBS improves quality of life and extends symptom-free periods compared to standard DBS. Lorenzo Rossi, CTO and Co-Founder, calls it a “defining moment” in neuromodulation, reinforcing the company’s mission to transform patient care. Expansion plans are also underway, with Newronika preparing for clinical trials in the U.S., a key step toward global adoption.